

Table of Contents

PART I. THE SEVEN STEP ANALYSIS

CHAPTER 1. YOUR FIRST LOOK AT A HEALTH CARE TRANSACTION: A SEVEN STEP ANALYSIS

- § 1:1 Introduction
- § 1:2 Step I: Identify the relevant parties and the health care businesses in which they are involved
- § 1:3 Step II: Identify the federal and state programs in which the parties participate or laws under which they are regulated
- § 1:4 Step III: Determine the nature of the transaction
- § 1:5 Step IV: Determine the governmental notices, approvals, and/or consents that will be required for the transaction
- § 1:6 Step V: Identify the relevant third party payment considerations
- § 1:7 Step VI: Determine the relevant health care “due diligence” requirements
- § 1:8 Step VII: Review pending and recently enacted state and federal regulations and legislation on health care reform and enforcement initiatives

APPENDIX 1:1. Types of Providers

APPENDIX 1:2. Types of Programs and Federal Agencies

PART II. THE TRANSACTION

CHAPTER 2. STATE REGULATION

I. IN GENERAL

§ 2:1 Introduction

II. LICENSURE, ACCREDITATION, AND REGISTRATION

§ 2:2 Generally

§ 2:3 Health care professionals

- § 2:4 Health care facilities
- § 2:5 Effect of licensure—Health care professionals
- § 2:6 —Health care facilities
- § 2:7 Accreditation

III. HEALTH PLANNING AND CERTIFICATE OF NEED

- § 2:8 In general
- § 2:9 Federal health planning laws
- § 2:10 State certificate of need laws
- § 2:11 Projects subject to CON review
- § 2:12 Transfer of ownership of an existing health care facility
- § 2:13 CON application and review process
- § 2:14 —Expedited review
- § 2:15 —Standard review
- § 2:16 —Review criteria
- § 2:17 Transferability of a certificate of need
- § 2:18 Enforcement
- § 2:19 Conclusion

APPENDIX 2:1. Sample Notice of Intent (Licensure)

APPENDIX 2:2. New York Form Required for Transfer of Ownership Interest (90/120 day) Notice Submissions—Transfer of Ownership Interest Notice Form

Appendix 2:3. Massachusetts Joint Committee on Health Care Financing section by section summary of An Act Enhancing The Market Review Process

CHAPTER 3. DISCLOSURE OF OWNERSHIP, ACCESS TO DOCUMENTS AND PROTECTION OF HEALTH INFORMATION

I. IN GENERAL

- § 3:1 Introduction

II. DISCLOSURE OF PERSONS HAVING OWNERSHIP, FINANCIAL, OR CONTROL INTERESTS UNDER MEDICARE PART A

- § 3:2 Generally
- § 3:3 Enhanced disclosures for nursing facilities under the Patient Protection and Affordable Care Act
- § 3:4 Direct ownership

TABLE OF CONTENTS

- § 3:5 Indirect ownership
- § 3:6 Controlling interests

III. DISCLOSURE OF IDENTITIES OF THOSE CONVICTED OF PROGRAM-RELATED OFFENSES OR SUBJECT TO ADMINISTRATIVE SANCTIONS

- § 3:7 Generally
- § 3:8 Agent
- § 3:9 Managing employees

IV. DISCLOSURE OF HIRING OF INTERMEDIARY'S FORMER EMPLOYEES

- § 3:10 Generally

V. DISCLOSURE OF BUSINESS TRANSACTIONS UPON REQUEST

- § 3:11 Generally

VI. DISCLOSURE OF OWNERSHIP, FINANCIAL, OR CONTROL INTERESTS UNDER MEDICARE PART B

- § 3:12 Generally

VII. DISCLOSURE OF PRINCIPALS CONVICTED OF A PROGRAM-RELATED CRIME

- § 3:13 Generally

VIII. DISCLOSURE OF BUSINESS TRANSACTIONS

- § 3:14 Generally

IX. DISCLOSURE OF PHYSICIAN FINANCIAL RELATIONSHIPS WITH ENTITIES FURNISHING MEDICARE COVERED DESIGNATED HEALTH SERVICES

- § 3:15 Generally

X. ACCESS TO RECORDS

- § 3:16 Generally
- § 3:17 Contracts to which the access clause applies
- § 3:18 Who has access
- § 3:19 Criteria for obtaining access

XI. DISCLOSURE AND USE OF PROTECTED HEALTH INFORMATION

- § 3:20 Disclosure and use of health information under the HIPAA privacy rule—Introduction
- § 3:21 The HIPAA privacy rule—Entities affected
- § 3:22 Types of protected health information
- § 3:23 Privacy protection requirements
- § 3:24 Public policy exceptions
- § 3:25 Protected health information used for research
- § 3:26 Protected health information used for marketing
- § 3:27 Protected health information used for fundraising
- § 3:28 “Business associates” of covered entities
- § 3:29 Sponsors of group health plans
- § 3:30 Patient privacy rights
- § 3:31 Penalties for improper disclosures
- § 3:32 Additional guidance regarding the HIPAA privacy standard

XII. CONCLUSION

- § 3:33 Privacy obligations related to electronic health records
- § 3:34 Federal notification standards for breaches of “unsecured” protected health information
- § 3:35 Application of HIPAA to due diligence in transactions with health care providers
- § 3:36 Disclosure and privacy concerns in transactions with health care providers

- APPENDIX 3:1. Medicare Enrollment Application for Institutional Providers (Form CMS-855A) and DMEPOS Suppliers (Form CMS-855S)
- APPENDIX 3:2. Sample Access Clause
- APPENDIX 3:3. Mobile Health App Developers: FTC Best Practices
- APPENDIX 3:4. Complying with the FTC’s Health Breach Notification Rule
- APPENDIX 3:5. HHS HIPAA Breach Notification Rule Guidance

CHAPTER 4. THE FEDERAL ANTI-KICKBACK LAW

- § 4:1 Introduction
- § 4:2 Penalties
- § 4:3 Statutory exceptions
- § 4:4 Relevant case law
- § 4:5 Private enforcement

TABLE OF CONTENTS

- § 4:6 Practical considerations
- § 4:7 —OIG Advisory Opinions on Health Care Fraud and Abuse Regulations
- § 4:8 Physicians at risk under the anti-kickback statute
- APPENDIX 4:1. Sample Contract Language on Improper Billing Practices or Payment Arrangements
- APPENDIX 4:2. Sample Fraud and Abuse Representations
- APPENDIX 4:3. Final Rule: Medicare and State Health Care Programs: Fraud and Abuse; Revisions to the Safe Harbors Under the Anti-Kickback Statute and Civil Monetary Penalty Rules Regarding Beneficiary Inducements
- APPENDIX 4:4. OIG Letter to PhRMA: Drug Companies that Provide Free Drugs to Federal Health Care Program Beneficiaries Impacted by Caring Voice Coalition, Inc.’s Decision Not to Provide Patient Assistance in 2018
- APPENDIX 4:5. October 2019 Fact Sheet on Notice of Proposed Rulemaking, “Revisions to the Safe Harbors Under the Anti-Kickback Statute and Civil Monetary Penalty Rules Regarding Beneficiary Inducements”
- APPENDIX 4:6. OIG Special Fraud Alert: Speaker Programs
- APPENDIX 4:7. OIG Advisory Opinion 20-08, December 30, 2020
- APPENDIX 4:8. Advisory Opinion 20-07, December 28, 2020
- Appendix 4:9. Advisory Opinion 21-01, March 23, 2021
- Appendix 4:10. Advisory Opinion 21-02, April 29, 2021
- Appendix 4:11. Advisory Opinion 21-03, May 17, 2021
- Appendix 4:12. Advisory Opinion 21-04, May 19, 2021
- Appendix 4:13. Advisory Opinion 21-05, May 20, 2021
- Appendix 4:14. Advisory Opinion 21-06, June 29, 2021
- Appendix 4:15. Advisory Opinion 21-07, July 7, 2021
- Appendix 4:16. Advisory Opinion 21-08, July 8, 2021
- Appendix 4:17. Advisory Opinion 21-09, July 19, 2021
- Appendix 4:18. Advisory Opinion 21-10, August 6, 2021
- Appendix 4:19. Advisory Opinion 21-11, August 19, 2021
- Appendix 4:20. Advisory Opinion 21-12, September 15, 2021
- Appendix 4:21. Advisory Opinion 21-13, October 4, 2021
- Appendix 4:22. Advisory Opinion 21-14, October 5, 2021
- Appendix 4:23. Advisory Opinion 21-15, November 10, 2021
- Appendix 4:24. Advisory Opinion 21-16, November 16, 2021

HEALTH FINANCIAL TRANSACTIONS

- Appendix 4:25. Advisory Opinion 21-17, November 19, 2021
- Appendix 4:26. Advisory Opinion 21-18, November 22, 2021
- Appendix 4:27. Advisory Opinion 21-19, December 6, 2021
- Appendix 4:28. Advisory Opinion 21-20, December 16, 2021
- Appendix 4:29. Advisory Opinion 22-01, January 19, 2022
- Appendix 4:30. Advisory Opinion 22-02, February 9, 2022
- Appendix 4:31. Advisory Opinion 22-03, February 14, 2022
- Appendix 4:32. Advisory Opinion 22-04, March 2, 2022
- Appendix 4:33. Advisory Opinion 22-05, March 16, 2022
- Appendix 4:34. Advisory Opinion 22-06, April 11, 2022
- Appendix 4:35. Advisory Opinion 22-07, April 25, 2022
- Appendix 4:36. Advisory Opinion 22-08, April 27, 2022
- Appendix 4:37. Advisory Opinion 22-09, April 28, 2022
- Appendix 4:38. Advisory Opinion 22-10, May 2, 2022
- Appendix 4:39. Advisory Opinion 22-11, May 25, 2022
- Appendix 4:40. Advisory Opinion 22-12, June 1, 2022
- Appendix 4:41. Modification of Advisory Opinion 20-02, June 1, 2022
- Appendix 4:42. Advisory Opinion 22-13, June 23, 2022
- Appendix 4:43. Advisory Opinion 22-14, June 29, 2022
- Appendix 4:44. Advisory Opinion 22-15, July 5, 2022
- Appendix 4:45. Advisory Opinion 22-16, August 19, 2022
- Appendix 4:46. Advisory Opinion 22-17, September 6, 2022
- Appendix 4:47. Advisory Opinion 22-18, September 20, 2022
- Appendix 4:48. Advisory Opinion 22-19, October 5, 2022
- Appendix 4:49. Advisory Opinion 22-20, December 19, 2022
- Appendix 4:50. Advisory Opinion 22-21, December 23, 2022
- Appendix 4:51. Advisory Opinion 22-22, December 28, 2022
- Appendix 4:52. Advisory Opinion 23-01, February 23, 2023
- Appendix 4:53. Advisory Opinion 23-02, February 28, 2023
- Appendix 4:54. Advisory Opinion 23-03, March 29, 2023
- Appendix 4:55. Advisory Opinion 23-04, July 11, 2023
- Appendix 4:56. Advisory Opinion 23-05, August 18, 2023
- Appendix 4:57. Advisory Opinion 23-06, September 28, 2023
- Appendix 4:58. Advisory Opinion 23-07, October 13, 2023
- Appendix 4:59. Advisory Opinion 23-08, October 25, 2023
- Appendix 4:60. Advisory Opinion 23-09, December 18, 2023

TABLE OF CONTENTS

- Appendix 4:61. Advisory Opinion 23-10, December 20, 2023
- Appendix 4:62. Advisory Opinion 23-11, December 27, 2023
- Appendix 4:63. Advisory Opinion 23-12, January 3, 2024
- Appendix 4:64. Advisory Opinion 23-13, January 3, 2024
- Appendix 4:65. Advisory Opinion 23-14, January 3, 2024
- Appendix 4:66. Advisory Opinion 23-15, January 3, 2024
- Appendix 4:67. Advisory Opinion 24-01, February 26, 2024
- Appendix 4:68. Advisory Opinion 24-02, April 11, 2024
- Appendix 4:69. Advisory Opinion 24-03, June 17, 2024
- Appendix 4:70. Advisory Opinion 24-04, June 20, 2024
- Appendix 4:71. Advisory Opinion 24-05, July 22, 2024
- Appendix 4:72. Advisory Opinion 24-06, July 23, 2024
- Appendix 4:73. Advisory Opinion 24-07 August 23, 2024
- Appendix 4:74. Advisory Opinion 24-08 September 13, 2024
- Appendix 4:75. Advisory Opinion 24-09 November 25, 2024
- Appendix 4:76. Advisory Opinion 24-10 December 12, 2024
- Appendix 4:77. Advisory Opinion 24-11 December 17, 2024
- Appendix 4:78. Advisory Opinion 24-12 December 17, 2024
- Appendix 4:79. Advisory Opinion 24-13 December 31, 2024
- Appendix 4:80. Advisory Opinion 25-01 January 15, 2025
- Appendix 4:81. Modification of Advisory Opinion Advisory
Opinion 21-13 February 12, 2025
- Appendix 4:82. Advisory Opinion 25-02 April 9, 2025
- Appendix 4:83. Advisory Opinion 25-03 June 11, 2025
- Appendix 4:84. Advisory Opinion 25-04 June 20, 2025
- Appendix 4:85. Advisory Opinion 25-05 June 30, 2025
- Appendix 4:86. Advisory Opinion 25-06 July 2, 2025
- Appendix 4:87. Advisory Opinion 25-07 July 2, 2025
- Appendix 4:88. Advisory Opinion 25-08 July 7, 2025

CHAPTER 5. FRAUD ALERTS, COMPLIANCE GUIDANCE, AND GUIDELINES FOR TAX-EXEMPT ORGANIZATIONS

I. OIG’S SPECIAL FRAUD ALERT ON JOINT VENTURES AND CONTRACTUAL ARRANGEMENTS

§ 5:1 Generally

- § 5:2 Investors
- § 5:3 Business structure
- § 5:4 Financing and profit distributions
- § 5:5 Application to physician investment in medical device manufacturers/distributors

II. OIG'S SPECIAL FRAUD ALERT ON HOSPITAL INCENTIVES TO PHYSICIANS

- § 5:6 Generally

III. OIG FRAUD ALERT ON PRESCRIPTION DRUG MARKETING SCHEMES AND RELATED DEVELOPMENTS

- § 5:7 Generally

IV. OIG'S SPECIAL FRAUD ALERT ON ARRANGEMENTS FOR THE PROVISION OF CLINICAL LAB SERVICES

- § 5:8 Generally
- § 5:9 Provision of phlebotomy services to physicians
- § 5:10 Lab pricing at renal dialysis centers
- § 5:11 Waiver of charges to managed care patients
- § 5:12 Other inducements

V. OIG'S SPECIAL FRAUD ALERT ON HOME HEALTH FRAUD

- § 5:13 Generally
- § 5:14 False or fraudulent claims
- § 5:15 Fraud in annual cost reports
- § 5:16 Kickbacks
- § 5:17 Abusive marketing practices

VI. OIG'S SPECIAL FRAUD ALERT ON THE PROVISION OF MEDICAL SUPPLIES TO NURSING FACILITIES

- § 5:18 Generally
- § 5:19 Claims for items that are not medically necessary
- § 5:20 Claims for items that are not provided as claimed or double billed
- § 5:21 Kickbacks
- § 5:22 Other fraudulent practices
- § 5:23 Nursing facility supply transactions

TABLE OF CONTENTS

VII. OIG’S MEDICARE ADVISORY BULLETIN ON HOSPICE BENEFITS AND OIG SPECIAL FRAUD ALERT ON NURSING HOME ARRANGEMENTS WITH HOSPICES

- § 5:24 OIG Medicare Advisory Bulletin on hospice benefits
- § 5:25 —Diagnosis of terminal disease
- § 5:26 —Health care needs relating to terminal condition
- § 5:27 —Complete and accurate information about hospice election
- § 5:28 Relaxation of the physician certification requirements
- § 5:29 OIG Special Fraud Alert on nursing home arrangements with hospices
- § 5:30 —Practices that constitute suspected kickbacks
- § 5:31 —Hospice payments to nursing homes for room and board
- § 5:32 —Hospice payments to nursing homes for additional services

VIII. OIG’S SPECIAL FRAUD ALERT ON THE PROVISION OF SERVICES IN NURSING FACILITIES

- § 5:33 Generally
- § 5:34 False or fraudulent claims
- § 5:35 What to look for

IX. OIG’S SPECIAL FRAUD ALERT ON PHYSICIAN LIABILITY FOR CERTIFICATIONS IN THE PROVISION OF MEDICAL EQUIPMENT AND SUPPLIES AND HOME HEALTH SERVICES

- § 5:36 Generally
- § 5:37 Proper physician certification procedures
- § 5:38 —Physician certification for home health services
- § 5:39 —Physician certification for DME, prosthetics, orthotics, and supplies for home use
- § 5:40 Consequences of improper physician certification

X. OIG’S SPECIAL ADVISORY BULLETIN ON HOSPITAL-PHYSICIAN “GAINSHARING”

- § 5:41 Generally
- § 5:42 Background
- § 5:43 OIG analysis in the Bulletin—Violation of provisions prohibiting payment to induce the reduction or limitation of services
- § 5:44 —Broad general pronouncement

- § 5:45 —Expeditious termination
- § 5:46 —Legitimate interest; legislative relief; permitted arrangements
- § 5:47 —Application to joint ventures and other arrangements
- § 5:48 Subsequent clarifications and determinations
- § 5:49 Gainsharing in federal court
- § 5:50 Changes to statutory language of the gainsharing CMP and Alternative payment models
- § 5:51 Implications for hospitals and physicians

XI. OIG’S UPDATED SPECIAL ADVISORY BULLETIN ON THE EFFECT OF EXCLUSION FROM PARTICIPATION IN FEDERAL HEALTH CARE PROGRAMS

- § 5:52 Generally
- § 5:53 Statutory expansion of OIG enforcement authority
- § 5:54 The OIG’s Updated Special Advisory Bulletin
- § 5:55 —Penalty for violating exclusionary provision
- § 5:56 —Ongoing employer/contractor responsibilities and suggested actions

XII. FEDERAL PATIENT ANTI-DUMPING STATUTE

- § 5:57 Summary of the Anti-Dumping Statute
- § 5:58 When a patient “Comes to the Emergency Department”
- § 5:59 Conducting a medical screening examination
- § 5:60 Providing stabilizing treatment or appropriate transfer
- § 5:61 Obtaining prior authorization for emergency care
- § 5:62 Application of EMTALA to hospital inpatients
- § 5:63 Administrative requirements under EMTALA
- § 5:64 Physician on-call coverage
- § 5:65 Obligations of receiving hospitals
- § 5:66 Penalties for EMTALA violations

XIII. OIG SPECIAL FRAUD ALERT: RENTAL OF SPACE IN PHYSICIAN OFFICES BY PERSONS OR ENTITIES TO WHICH THE PHYSICIAN REFERS

- § 5:67 Generally
- § 5:68 Questionable arrangements
- § 5:69 —Appropriateness of rental agreement: Application to DMEPOS suppliers
- § 5:70 —Rental amounts
- § 5:71 —Time and space considerations

TABLE OF CONTENTS

- § 5:72 Rental amount calculations
- § 5:73 —Exclusive office space
- § 5:74 —Interior office common space
- § 5:75 —Building common space
- § 5:76 Safe harbor protection

**XIV. OIG SPECIAL ADVISORY BULLETIN:
PRACTICES OF BUSINESS CONSULTANTS**

- § 5:77 Generally
- § 5:78 Questionable practices
- § 5:79 Illegal or misleading representations
- § 5:80 Promises and guarantees
- § 5:81 Encouraging abusive practices
- § 5:82 Discouraging compliance efforts

**XV. OIG SPECIAL ADVISORY BULLETIN:
OFFERING GIFTS AND OTHER
INDUCEMENTS TO BENEFICIARIES AND
RECENT SAFE HARBORS FOR PERMITTED
ARRANGEMENTS**

- § 5:83 Generally
- § 5:84 Background
- § 5:85 OIG analysis
- § 5:86 —Elements of the prohibition
- § 5:87 —OIG principles for applying the inducement
prohibition
- § 5:88 —Providing benefits through independent entities
- § 5:89 Additional regulatory considerations
- § 5:90 Implications

**XVI. OIG SPECIAL FRAUD ALERT:
TELEMARKETING BY DURABLE MEDICAL
EQUIPMENT SUPPLIERS**

- § 5:91 Generally

**XVII. OIG SPECIAL FRAUD ALERT: PHYSICIAN-
OWNED ENTITIES**

- § 5:92 Generally

**XVIII. OIG SPECIAL ADVISORY BULLETIN:
CONTRACTUAL JOINT VENTURES**

- § 5:93 Generally
- § 5:94 Specimen processing arrangements

- § 5:95 Registry arrangements
- § 5:96 Generally
- § 5:97 Background
- § 5:98 Provisions of advisory bulletin
- § 5:99 —Questionable contractual arrangements
- § 5:100 —Unavailability of safe harbor protection
- § 5:101 —Indicia of a suspect contractual joint venture
- § 5:102 Implications for health care entities

XIX. SOLICITATION OF ADDITIONAL FRAUD ALERTS

- § 5:103 Generally

XX. OIG GUIDANCE ON HOSPITAL DISCOUNTS

- § 5:104 Generally

XXI. OIG GUIDANCE ON PART D PATIENT ASSISTANCE PROGRAMS

- § 5:105 Generally

XXII. COMPLIANCE PROGRAM GUIDANCE DOCUMENTS

- § 5:106 Compliance program guidance documents
- § 5:107 HHS OIG General Compliance Program Guidance (November 2023)
- § 5:108 OIG nursing facility industry segment—Specific compliance program guidance (November 2024)

XXIII. IRS GUIDANCE FOR TAX-EXEMPT HOSPITALS

- § 5:109 Generally
- § 5:110 —Intermediate sanctions
- § 5:111 —Physician incentives
- § 5:112 —Joint ventures
- § 5:113 Joint venture under Revenue Ruling 98–15
- § 5:114 *St. David's Healthcare System* tax exemption for participant in whole hospital joint venture
- § 5:115 Internal Revenue Service Revenue Ruling on tax exemption and unrelated business taxable income consequences for participant in ancillary joint venture
- § 5:116 IRS guidance on governance
- § 5:117 New ACA requirements for tax-exempt hospitals
- § 5:118 IRS guidance for Charitable Hospitals

TABLE OF CONTENTS

XXIV. OIG SPECIAL FRAUD ALERT: SUSPECT PAYMENTS IN MARKETING ARRANGEMENTS RELATED TO MEDICARE ADVANTAGE AND PROVIDERS (12-11-24)

§ 5:119 Generally

- Appendix 5:1. Special Fraud Alert: Joint Venture Arrangements
- Appendix 5:2. Management Agreement—“Shell” Analysis Checklist
- Appendix 5:3. Joint Venture/Partnership Checklist
- Appendix 5:4. Special Fraud Alert: Hospital Incentives to Physicians
- Appendix 5:5. Special Fraud Alert: Prescription Drug Marketing Schemes
- Appendix 5:6. IRS Sample Conflict of Interest Policy
- Appendix 5:7. Medicare Advisory Bulletin on Hospice Benefits
- Appendix 5:8. Practices of business consultants
- Appendix 5:9. Special Fraud Alert: Fraud and Abuse in the Provision of Services in Nursing Facilities
- Appendix 5:10. Special Fraud Alert: Fraud and Abuse in Nursing Home Arrangements with Hospices
- Appendix 5:11. OIG Special Fraud Alert: Physician Liability for Certifications in the Provision of Medical Equipment and Supplies and Home Health Services
- Appendix 5:12. Special Advisory Bulletin: Gainsharing Arrangements and CMPs for Hospital Payments to Physicians to Reduce or Limit Services to Beneficiaries
- Appendix 5:13. Special Advisory Bulletin on the Effect of Exclusion from Participation in Federal Health Care Programs
- Appendix 5:14. OIG/HCFR Special Advisory Bulletin on the Patient Anti-Dumping Statute
- Appendix 5:15. Special Fraud Alert: Rental of Space in Physician Offices by Persons or Entities to Which the Physician Refers
- Appendix 5:16. Office of Inspector General: Special Advisory Bulletin, Offering Gifts and Other Inducements to Beneficiaries
- Appendix 5:17. Office of Inspector General: Special Fraud

- Alert, Telemarketing By Durable Medical Equipment Suppliers
- Appendix 5:18. Office of Inspector General: Special Fraud Alert, Physician-Owned Entities
- Appendix 5:19. Office of Inspector General: Special Advisory Bulletin, Contractual Joint Ventures
- Appendix 5:20. OIG Guidance on IRO Independence and Objectivity
- Appendix 5:21. OIG Advisory Opinion 19-03
- Appendix 5:22. Advisory Opinion 19-01
- Appendix 5:23. Advisory Opinion 18-12
- Appendix 5:24. Advisory Opinion 18-05
- Appendix 5:25. Health Care Fraud Self-Disclosure Protocol (updated November 8, 2021)
- Appendix 5:26. OIG Advisory Opinion 19-5, September 11, 2019
- Appendix 5:27. 2020 OIG Enforcement Actions and Exclusions
- Appendix 5:28. 2021 OIG Enforcement Actions and Exclusions
- Appendix 5:29. 2022 OIG Enforcement Actions and Exclusions
- Appendix 5:30. 2023 OIG Enforcement Actions and Exclusions
- Appendix 5:31. 2024 OIG Enforcement Actions and Exclusions
- Appendix 5:32. Special Fraud Alert: OIG Alerts Practitioners To Exercise Caution When Entering Into Arrangements With Purported Telemedicine Companies (July 20, 2022)
- Appendix 5:33. CMS Questions on Charges for the Uninsured
- Appendix 5:34. OIG Frequently Asked Questions: General Questions Regarding Certain Fraud and Abuse Authorities
- Appendix 5:35. 2025 OIG Enforcement actions and exclusions

CHAPTER 6. SAFE HARBOR REGULATIONS

I. CATEGORIES OF SAFE HARBORS

§ 6:1 Generally

II. INVESTMENT INTEREST SAFE HARBORS

§ 6:2 Generally

TABLE OF CONTENTS

- § 6:3 Large publicly traded entities
- § 6:4 Small entities
- § 6:5 Investment interests in entities in rural areas
- § 6:6 Investment interests in ambulatory surgical centers
- § 6:7 Practitioner investment in a group practice

III. PRACTITIONER COMPENSATION SAFE HARBORS

- § 6:8 Employee safe harbor
- § 6:9 Practitioner recruitment
- § 6:10 Obstetrical malpractice insurance subsidies

IV. PERSONAL SERVICES AND MANAGEMENT CONTRACTS, AND SPACE AND EQUIPMENT RENTAL SAFE HARBORS

- § 6:11 Generally

V. SALE OF PRACTICE SAFE HARBOR

- § 6:12 Generally

VI. SAFE HARBORS FOR ELECTRONIC PRESCRIBING AND HEALTH RECORDS ARRANGEMENTS

- § 6:13 Generally

APPENDIX 6:1. Fraud and Abuse Checklist

APPENDIX 6:2. HHS Office of Inspector General Fact Sheet:
Final Rule: Revisions to the Safe Harbors
Under the Anti-Kickback Statute and Civil
Monetary Penalty Rules Regarding
Beneficiary Inducements; November 2020

CHAPTER 7. FALSE CLAIMS ACT, CIVIL MONEY PENALTIES, EXCLUSIONS AND OTHER SANCTIONS

I. IN GENERAL

- § 7:1 Introduction

II. EXCLUSIONS FROM FEDERAL HEALTH CARE PROGRAM PARTICIPATION

- § 7:2 Generally
- § 7:3 Mandatory exclusions

§ 7:4 Permissive exclusions

III. CIVIL MONEY PENALTIES

§ 7:5 Generally

IV. PROGRAM FRAUD CIVIL REMEDIES ACT

§ 7:6 Generally

V. MEDICARE FALSE CLAIMS ACT

§ 7:7 Generally

VI. FEDERAL FALSE CLAIMS ACT AND CITIZEN ENFORCEMENT PROVISIONS

§ 7:8 Generally

VII. OTHER CRIMINAL OFFENSES UNDER MEDICARE PROGRAM

§ 7:9 Generally

VIII. FEDERAL GOVERNMENT ANTI-FRAUD, ABUSE AND WASTE INITIATIVES

§ 7:10 Generally

§ 7:11 Targeted federal health fraud enforcement initiatives

§ 7:12 OIG work plan

§ 7:13 —Hospital reviews

§ 7:14 —Home health reviews

§ 7:15 —Nursing home reviews

§ 7:16 —Hospice reviews

§ 7:17 —Physicians and other providers and suppliers

§ 7:18 —Medical equipment and supplies

§ 7:19 —Medicare Part D

§ 7:20 —Part B Payments for Prescription Drugs

§ 7:21 —Medicare contractor operations

§ 7:22 —Medicare Advantage

§ 7:23 —Medicaid drug reimbursement reports

§ 7:24 —Medicaid services

§ 7:25 —Other issues

§ 7:26 —Investigations and other legal issues

§ 7:27 Fraud and abuse control program

§ 7:28 Corporate integrity agreement FAQs

§ 7:29 Medicaid Fraud Control Units Annual Report: Fiscal Year 2024

TABLE OF CONTENTS

**CHAPTER 8. CHANGES OF OWNERSHIP
AND NEW BUSINESS ORGANIZATIONS:
REIMBURSEMENT CONSIDERATIONS**

I. CHANGE OF OWNERSHIP

- § 8:1 Generally
- § 8:2 Transactions that constitute a change of ownership for Medicare purposes—Partnership
 - § 8:3 —Unincorporated sole proprietorship
 - § 8:4 —For profit corporations
 - § 8:5 —Nonprofit corporations
 - § 8:6 —Limited liability companies
 - § 8:7 —Leasing
- § 8:8 Implications of a change of ownership
- § 8:9 Change of ownership and long-term care hospitals
- § 8:10 Change of ownership and skilled nursing facilities and nursing facilities
- § 8:11 Change of ownership and home health agencies
- § 8:12 Change of ownership for Medicaid purposes

II. RELATED ORGANIZATIONS

- § 8:13 Generally
- § 8:14 Common ownership or control issues—Ownership
 - § 8:15 —Option to purchase ownership interests in the provider
 - § 8:16 —Control
 - § 8:17 —Fixed-term loan
 - § 8:18 —Cumulative effect
- § 8:19 Exception to the related organization rule for substantial business with unrelated parties
- § 8:20 Practical issues

**III. STATUTE OF LIMITATIONS ON COLLECTING
OVERPAYMENTS FROM PROVIDERS**

- § 8:21 Generally

IV. SUCCESSOR LIABILITY

- § 8:22 Generally

V. PROVIDER-BASED STATUS

- § 8:23 Background
- § 8:24 Application of standards
- § 8:25 Site-neutral payment policy for certain newly-acquired,

- provider-based, off-campus hospital outpatient departments
- § 8:26 Definitions
- § 8:27 Responsibility for obtaining provider based determinations
- § 8:28 When a determination becomes effective
- § 8:29 Reporting requirements
- § 8:30 Operational requirements for provider-based status applicable to all subordinate facilities
- § 8:31 Additional requirements for off-campus subordinate facilities
- § 8:32 Joint ventures
- § 8:33 Obligations of hospital outpatient departments and hospital-based entities
- § 8:34 Management contracts
- § 8:35 Services under arrangement
- § 8:36 Inappropriate treatment of a facility or organization as provider-based and inappropriate billing
- § 8:37 Temporary treatment and correction of errors
- § 8:38 Status of Indian health service and tribal facilities—
Status of FQHCs and “Look-Alikes”
- APPENDIX 8:1. Sample Contract Language on Medicare and Medicaid Payment Liabilities
- APPENDIX 8:2. Sample Medicare Notice of Change of Ownership
- APPENDIX 8:3. CMS Survey and Certification Group Letter

Table of Contents

PART II. THE TRANSACTION (CONTINUED)

CHAPTER 9. THE STARK LAW AND OTHER PHYSICIAN SELF-REFERRAL RESTRICTIONS

I. IN GENERAL

§ 9:1 Introduction

II. OVERVIEW OF STARK

- § 9:2 Basic standard and dual prohibitions
- § 9:3 Penalties/sanctions
- § 9:4 Definitions—Physician and immediate family member
- § 9:5 —Referral
- § 9:6 —DHS
- § 9:7 The Medicare Anti-Markup Rule
- § 9:8 Definitions—Entity/furnishing
- § 9:9 Financial relationships
- § 9:10 —Direct ownership or investment interests
- § 9:11 —Indirect ownership or investment interests
- § 9:12 —Direct compensation arrangements/stand in the shoes
- § 9:13 —Indirect compensation arrangements
- § 9:14 Exceptions—Ownership exceptions
- § 9:15 — —Publicly traded securities and mutual funds
- § 9:16 — —Hospitals located in Puerto Rico
- § 9:17 — —Rural providers
- § 9:18 — —Whole hospital exception
- § 9:19 —Compensation arrangement exceptions
- § 9:20 — —Rental of office space
- § 9:21 — —Rental of equipment
- § 9:22 — —Personal service arrangements
- § 9:23 — —Isolated transactions
- § 9:24 — —Fair market value compensation
- § 9:25 —Assistance to compensate a nonphysician practitioner
- § 9:26 —Timeshare arrangements

- § 9:27 —Compensation arrangement exceptions—Indirect compensation arrangements
- § 9:28 —Multi-purpose exceptions
- § 9:29 — —Physician services
- § 9:30 — —In-office ancillary services
- § 9:31 —Temporary non-compliance exception
- § 9:32 Self-referral disclosure protocol

III. APPLICATION OF STARK LAW TO SELECTED BUSINESS MODELS/TRANSACTIONS

- § 9:33 DHS Entity—Physician group space lease—Factual example
- § 9:34 — —Potential application of exception
- § 9:35 —Physician personal services arrangement—Factual example
- § 9:36 — —Potential application of exception
- § 9:37 Physician group and pathology laboratory—Factual example
- § 9:38 —Potential application of exception
- § 9:39 Joint ventures/services furnished “under arrangements”—Factual example
- § 9:40 —Potential application of exception

IV. STATE LAW

- § 9:41 Generally
- § 9:42 Arizona
- § 9:43 California
- § 9:44 Florida
- § 9:45 —Designated health services
- § 9:46 —Other health services
- § 9:47 —Definitional exceptions to both prohibitions
- § 9:48 Kentucky
- § 9:49 Maryland
- § 9:50 Michigan
- § 9:51 New Hampshire
- § 9:52 New Jersey
- § 9:53 Ohio

V. CONCLUSION

- § 9:54 Generally

APPENDIX 9:1. Memorandum from Claudia Foutz, Arizona Board of Medical Examiners, to Arizona Licensees (March 2000)

APPENDIX 9:2. Corporate Integrity Agreement Between the Office of Inspector General of the

TABLE OF CONTENTS

- Department Of Health And Human Services
Health Quest Systems, Inc., Health Quest
Medical Practice, P.C., Health Quest Urgent
Medical Care Practice, P.C., And Health
Quest Home Health Care, Inc. (with several
Stark Act references)
- APPENDIX 9:3. CMS-Advisory Opinion 2017-01—Concerning
whether the addition of certain information
to a free web-based portal, which is used for
ordering and communicating the results of
diagnostic tests, would constitute
“remuneration” that gives rise to a
“compensation arrangement” under section
1877(h)(1) of the Social Security Act
- APPENDIX 9:4. CMS-AO-2016-01—Concerning whether a
physician-owned hospital’s addition of
certain observation beds, which are not
licensed by the state where the hospital is
located, would violate the limitation on
expansion of facility capacity set forth in
section 1877(i)(1)(B) of the Social Security
Act
- APPENDIX 9:5. CMS Physician Self-Referral Law FAQs
(Updated 09/20/2021)
- APPENDIX 9:6. CMS Advisory Opinion—CMS-AO-2019-01—
Concerning Whether Certain of a Physician-
Owned Hospital’s Operating Rooms May Be
Counted When Determining the Hospital’s
Aggregate Number of Licensed Beds,
Procedure Rooms, and Operating Rooms as
of March 23, 2010 Under Section
1877(i)(1)(B) of the Social Security Act (the
“Act”) and 42 C.F.R. § 411.362(b)(2)
- APPENDIX 9:7. CMS Advisory Opinion—CMS-AO-2020-01—
Concerning whether certain of a physician-
owned hospital’s operating rooms and
inpatient beds may be counted when
determining the hospital’s aggregate
number of licensed beds, procedure rooms,
and operating rooms as of March 23, 2010
under section 1877(i)(1)(B) of the Social
Security Act and 42 C.F.R. § 411.362(b)(2)
(PDF)
- Appendix 9:8. CMS/OIG Medicare Shared Savings Program
Waivers: Special ACO Pre-Participation
Waiver Guidance for the 2021 Application
Cycle (Issued: May 8, 2020)
- Appendix 9:9. OIG Notice of Waiver of Certain Fraud and

Abuse Laws in Connection With the
Primary Care First Component of the
Primary Care First Model (issued December
16, 2020)

Appendix 9:10. CMS Expansion Exception Process: Accessing
HCRIS Data and Sample Computations
(updated January 4, 2022)

CHAPTER 10. CORPORATE PRACTICE OF MEDICINE

I. IN GENERAL

§ 10:1 Introduction

II. THE DOCTRINE

§ 10:2 Statement of the prohibition and underlying rationale

§ 10:3 Historical basis

§ 10:4 Public policy considerations

III. ENFORCEMENT OF THE DOCTRINE

§ 10:5 Mechanisms for enforcement

§ 10:6 Applications of the doctrine

§ 10:7 —California

§ 10:8 —Texas

§ 10:9 —Massachusetts

§ 10:10 —New York

§ 10:11 —New Jersey

§ 10:12 —Colorado

§ 10:13 —Pennsylvania

§ 10:14 —Illinois

IV. EROSION OF THE DOCTRINE

§ 10:15 New realities and the abandonment of established
precedents

§ 10:16 *AMA v. FTC*

§ 10:17 Recognized exceptions to the doctrine

§ 10:18 —Hospitals

§ 10:19 —MCOs

§ 10:20 —Management service contracts

§ 10:21 —Freestanding emergency centers

V. CONCLUSION

§ 10:22 Generally

TABLE OF CONTENTS

**CHAPTER 11. MANAGED CARE AND
INTEGRATED DELIVERY SYSTEMS**

I. IN GENERAL

§ 11:1 Introduction

II. TYPES OF MANAGED CARE ORGANIZATIONS

§ 11:2 Generally

§ 11:3 Health maintenance organizations

§ 11:4 —Staff model HMO

§ 11:5 —Group model HMO

§ 11:6 —Network model HMO

§ 11:7 —Independent Practice Association (IPA) model HMO

§ 11:8 Preferred provider organizations

§ 11:9 —Provider owned PPOs

§ 11:10 —Insurance owned PPOs

§ 11:11 —Employer owned PPOs

§ 11:12 —Independent investors and broker owned PPOs

§ 11:13 —HMO or TPA owned PPOs

§ 11:14 Point-of-service plans

§ 11:15 Physician hospital organizations

§ 11:16 Integrated Delivery System

III. ELEMENTS OF MANAGED CARE PROGRAMS

§ 11:17 Generally

IV. REGULATION OF MANAGED CARE ENTITIES

§ 11:18 Regulation of HMOs—State regulation

§ 11:19 —Federal regulation

§ 11:20 PPOs

§ 11:21 Point of service plans

§ 11:22 Accreditation

V. COMPENSATION OF PROVIDERS

§ 11:23 Generally

§ 11:24 Regulation of provider payments

§ 11:25 Narrow and tiered networks

§ 11:26 New sites of service

**VI. EMPLOYER-BASED AND UNION-BASED
MANAGED CARE PLANS**

§ 11:27 Generally

§ 11:28 ERISA preemption

§ 11:29 Liability of an employer-based plan

VII. ANTITRUST CONCERNS

§ 11:30 Generally

VIII. UTILIZATION REVIEW

§ 11:31 Generally

IX. GOVERNMENT MANAGED CARE PROGRAMS

§ 11:32 Medicare managed care

§ 11:33 Medicaid managed care

§ 11:34 State children's health insurance program

§ 11:35 Managed care fraud and abuse

X. STATE "ANY WILLING PROVIDER" LAWS

§ 11:36 Generally

§ 11:37 State developments

§ 11:38 Out-of-network litigation

XI. ACCOUNTABLE CARE ORGANIZATIONS

§ 11:39 Generally

XII. BUNDLED PAYMENT INITIATIVES

§ 11:40 Generally

CHAPTER 12. ACCOUNTS RECEIVABLE FINANCING

I. IN GENERAL

§ 12:1 Introduction

II. SCOPE OF FEDERAL MEDICARE AND MEDICAID PROHIBITIONS

§ 12:2 Generally

§ 12:3 Medicare

§ 12:4 Medicaid—Federal law

§ 12:5 —State law

§ 12:6 Statutory and regulatory exceptions

§ 12:7 —Medicare exceptions

§ 12:8 — —Exceptions common to Medicare Parts A and B—
Payment to a billing agent

§ 12:9 — — —Court-ordered assignments

TABLE OF CONTENTS

§ 12:10 — —Additional Medicare Part B exceptions

§ 12:11 — —Medicaid exceptions

III. FEDERAL ASSIGNMENT OF CLAIMS ACT

§ 12:12 Generally

IV. ASSIGNMENT OF VETERANS' BENEFITS

§ 12:13 Generally

V. PROTECTING THE LENDER

§ 12:14 Generally

§ 12:15 Due diligence—Outstanding secured commitments

§ 12:16 Limiting the scope of receivables subject to the program

§ 12:17 Representations, warranties, and covenants

§ 12:18 Requirement to repurchase

§ 12:19 Enforcement

§ 12:20 Default and payment under court-ordered assignments

APPENDIX 12:1. Letter Dated September 22, 1988, from Kathleen A. Buto to Thomas C. Fox

APPENDIX 12:2. Letter Dated December 17, 1991, from Alan E. Reider to Kathleen A. Buto

APPENDIX 12:3. Letter Dated December 24, 1991, from Kathleen A. Buto to Alan E. Reider

CHAPTER 13. INITIAL PUBLIC OFFERINGS

I. IN GENERAL

§ 13:1 Introduction

II. MARKET OVERVIEW OF HEALTH CARE IPOs

§ 13:2 Overview

§ 13:3 Health care IPO trends: 1990-present

III. INITIAL PUBLIC OFFERINGS

§ 13:4 Generally

§ 13:5 The participants

§ 13:6 — —The underwriter

§ 13:7 — —Counsel—Issuer's counsel

§ 13:8 — —Underwriter's counsel

- § 13:9 —Accountants
- § 13:10 —Securities and Exchange Commission
- § 13:11 —State securities reviewers
- § 13:12 —Financial Industry Regulatory Authority (FINRA)
- § 13:13 The registration process—Structuring the underwriting relationship
- § 13:14 —Engagement letter
- § 13:15 —Preparing the registration statement
- § 13:16 —Managing company communications
- § 13:17 Marketing the IPO
- § 13:18 —Underwriting group
- § 13:19 —Selling group
- § 13:20 —Preliminary prospectus
- § 13:21 —Roadshow
- § 13:22 —Execution of the underwriting agreement

IV. SUBSEQUENT PUBLIC OFFERINGS

- § 13:23 Generally

V. LIFE AS A PUBLIC COMPANY

- § 13:24 Periodic filings
- § 13:25 Regulation FD
- § 13:26 Ownership of equity securities of a public company
- § 13:27 Sarbanes-Oxley Act of 2002

APPENDIX 13:1. Amendment No. One to 1Life Healthcare, Inc. Form S-1 filed with SEC

CHAPTER 14. BOND FINANCING

I. OVERVIEW: TAX AND CORPORATE ISSUES

- § 14:1 Introduction
- § 14:2 Selected tax issues—Tax-exempt bonds
- § 14:3 —Issuer
- § 14:4 —Tax-exempt status of provider
- § 14:5 —Use of bond proceeds
- § 14:6 — —Unrelated trade or business
- § 14:7 — —Mixed use facilities
- § 14:8 — —Physician contracts and management agreements
- § 14:9 — —Research facilities
- § 14:10 — —Joint venture arrangements
- § 14:11 —\$150 million limitation
- § 14:12 —Weighted average maturity limitation; pooled financings

TABLE OF CONTENTS

- § 14:13 —Limitation on reimbursement for capital expenditures
- § 14:14 —Refunding bonds
- § 14:15 —Other tax matters
- § 14:16 —Change in use or ownership
- § 14:17 —Taxable bonds; IRS Enforcement Activity; VCAP; Bank Qualified Bonds
- § 14:18 Corporate considerations—Issuer
- § 14:19 —Bonds—Generally
- § 14:20 — —Derivatives
- § 14:21 —Indenture
- § 14:22 —Master indentures
- § 14:23 —Transfer of bond proceeds; repayment obligation
- § 14:24 —Credit enhancement
- § 14:25 —Representations and warranties, covenants, etc.
- § 14:26 —Bond ratings
- § 14:27 —Continuing disclosure

CHAPTER 15. DISTRESSED PROVIDERS— BANKRUPTCY AND CREDITORS' RIGHTS

I. IN GENERAL

- § 15:1 Introduction

II. CREDITORS IN THE PREBANKRUPTCY CONTEXT

- § 15:2 Generally

III. BANKRUPT PROVIDER'S ABILITY TO CONTINUE TO PARTICIPATE IN MEDICARE

- § 15:3 Generally

IV. EFFECT OF BANKRUPTCY ON STREAM OF REVENUE: PROVIDER'S ABILITY TO RECEIVE PAYMENT AND INTERMEDIARIES' POWER TO RECOVER OVERPAYMENTS

- § 15:4 Generally

V. OTHER BANKRUPTCY ISSUES

- § 15:5 Generally
- § 15:6 HMO bankruptcies
- § 15:7 Corporate veil issues
- § 15:8 Licensure and certificate of need issues

- § 15:9 Successor liability if health care provider's Medicare provider number is sold through bankruptcy process
- § 15:10 Successor liability in bankruptcy for depreciation recapture
- § 15:11 Storage of patient records where debtor is a "health care business"
- § 15:12 Appointment of patient care ombudsman
- § 15:13 Trustee's duty to transfer patients of health care business
- § 15:14 Administrative expense claim for closing health care business

PART III. QUICK REFERENCE GUIDE TO THE HEALTH CARE INDUSTRY: PLAYERS AND PAYORS

CHAPTER 16. THE HEALTH CARE INDUSTRY

I. IN GENERAL

- § 16:1 Introduction

II. HOSPITALS

- § 16:2 Generally
- § 16:3 Acute care hospitals
- § 16:4 Psychiatric hospitals
- § 16:5 Long-term care hospitals (LTCHs)
- § 16:6 Rehabilitation hospitals
- § 16:7 "Specialty hospitals"

III. LONG-TERM CARE FACILITIES

- § 16:8 Nursing facilities (NFs) and skilled nursing facilities (SNFs)
- § 16:9 Continuing care retirement communities (CCRCs)
- § 16:10 Intermediate care facilities for individuals with intellectual disabilities (ICFs/IID)

IV. OUTPATIENT AND REHABILITATION FACILITIES

- § 16:11 Generally
- § 16:12 Ambulatory surgical centers (ASCs)
- § 16:13 Comprehensive outpatient rehabilitation facilities (CORFs)

TABLE OF CONTENTS

- § 16:14 End-stage renal disease (ESRD) facilities
- § 16:15 Rehabilitation agencies

V. HOME CARE PROVIDERS

- § 16:16 Generally
- § 16:17 Durable medical equipment (DME) suppliers
- § 16:18 Home health agencies (HHAs) and private duty nursing agencies
- § 16:19 Home infusion suppliers
- § 16:20 Hospices

VI. PRIMARY CARE PROVIDERS

- § 16:21 Generally
- § 16:22 Physicians
- § 16:23 Rural health clinics (RHCs)

VII. INDEPENDENT DIAGNOSTIC TESTING FACILITY

- § 16:24 Introduction
- § 16:25 Entities required to enroll as IDTFs
- § 16:26 IDTF performance standards
- § 16:27 IDTF supervising physician requirements—General supervision
- § 16:28 —Direct and personal supervision
- § 16:29 —Proficiency
- § 16:30 Requirements for non-physician personnel
- § 16:31 Order requirements
- § 16:32 Multi-state entities
- § 16:33 IDTF enrollment not required—Companies that lease/contract diagnostic testing equipment and/or non-physician personnel
- § 16:34 —Joint venture between a radiology group and a hospital
- § 16:35 Medicare Improvements for Patients and Providers Act of 2008 (MIPPA)

VIII. MISCELLANEOUS PROVIDERS

- § 16:36 Generally
 - § 16:37 Clinical laboratories
 - § 16:38 Manufacturers of drugs and medical devices
 - § 16:39 Pharmacies
- Appendix 16:1. CMS Guidance for time-share and leased space arrangements in Critical Access Hospitals (CAHs) (November 2024)

CHAPTER 17. THE MEDICARE PROGRAM

I. OVERVIEW AND ADMINISTRATION

§ 17:1 Generally

II. ELIGIBILITY AND COVERAGE

§ 17:2 Eligibility

§ 17:3 Coverage

§ 17:4 Reimbursement

III. PROSPECTIVE PAYMENT SYSTEMS FOR INPATIENT AND OUTPATIENT HOSPITAL SERVICES

§ 17:5 Generally

§ 17:6 Overview of IPPS

§ 17:7 Classification and calculation of DRGs/MS-DRGs

§ 17:8 Reimbursement

§ 17:9 Revisions to DRG/MS-DRG classifications

§ 17:10 Additional payments made under the IPPS

§ 17:11 —Disproportionate share hospitals

§ 17:12 —Indirect medical education

§ 17:13 —Reimbursement for undocumented immigrants

§ 17:14 —Outlier cases

§ 17:15 —Direct graduate medical education

§ 17:16 —ESRD discharges

§ 17:17 —Blood clotting factor costs

§ 17:18 —Miscellaneous excluded (pass-through) costs

§ 17:19 —MMA linkage between reimbursement and quality

§ 17:20 Inpatient hospital provisions in the Affordable Care Act

§ 17:21 Outpatient hospital services—Overview

§ 17:22 Annual revisions

§ 17:23 Outpatient hospital provisions in the Affordable Care Act

§ 17:24 Conclusion

IV. REASONABLE COST REIMBURSEMENT AND THE RELATED ORGANIZATION RULE

§ 17:25 Reasonable cost reimbursement

§ 17:26 —Reasonable costs

§ 17:27 —Payment methodology

§ 17:28 Related organization rule

§ 17:29 —Common ownership

§ 17:30 —Control

TABLE OF CONTENTS

§ 17:31 —Exception to related organization rule

V. PAYMENTS FOR PHYSICIANS: RESOURCE-BASED RELATIVE VALUE SCALE (RBRVS)

- § 17:32 Introduction
- § 17:33 Background
- § 17:34 RBRVS methodology
- § 17:35 Recent physician fee schedule developments—
MACRA reforms
- § 17:36 Physician reimbursement provisions in the Affordable
Care Act
- § 17:37 Participating physicians and restrictions on physician
balance billing
- § 17:38 Opting out of Medicare/private contracts

**VI. NONINSTITUTIONAL SERVICES: PAYMENTS
BASED ON FEE SCHEDULES**

- § 17:39 Generally
- § 17:40 Laboratory services
- § 17:41 Durable medical equipment
- § 17:42 Orthotics, prosthetics, and prosthetic devices
- § 17:43 Renal dialysis services
- § 17:44 Radiology services
- § 17:45 Rehabilitation services
- § 17:46 Ambulance services

**VII. PROSPECTIVE PAYMENT SYSTEM FOR
SKILLED NURSING FACILITIES**

- § 17:47 Introduction
- § 17:48 Summary of Medicare payments prior to BBA
amendments
- § 17:49 Medicare payments following BBA amendments—
Overview
- § 17:50 Medicare payments—Resource Utilization Group,
Version IV (RUG-IV)—Overview
- § 17:51 — —RUG assignment
- § 17:52 — —Schedule of MDS assessments
- § 17:53 — —Federal payment rates—Overview
- § 17:54 — —Rate updates
- § 17:55 Consolidated billing
- § 17:56 Proposed Resident Classification System

**VIII. PROSPECTIVE PAYMENT SYSTEM FOR
HOME HEALTH AGENCIES**

- § 17:57 Generally

IX. PROSPECTIVE PAYMENT SYSTEM FOR INPATIENT REHABILITATION FACILITIES

- § 17:58 Generally
- § 17:59 IRF classification
- § 17:60 IRF Payment—Conditions of coverage
- § 17:61 IRF Payment System—Patient assessment
- § 17:62 —Admission and discharge assessments
- § 17:63 —Interrupted stays
- § 17:64 —Encoding and transmission
- § 17:65 —Penalties
- § 17:66 —Patients' rights
- § 17:67 —Case-mix group (CMG)
- § 17:68 Case-mix group (CMG)—Adjustment of the CMGs
- § 17:69 Payment rates
- § 17:70 —Transfer cases
- § 17:71 —Special non-transfer cases
- § 17:72 Quality Reporting Program

X. PROSPECTIVE PAYMENT SYSTEM FOR LONG TERM CARE HOSPITALS

- § 17:73 Background
- § 17:74 Definition of LTCHs
- § 17:75 Patient classification
- § 17:76 Coding procedures
- § 17:77 Payment provisions—Generally
- § 17:78 —Development of LTC-DRG relative weights
- § 17:79 —Special cases—Short-stay outliers
- § 17:80 — —Interrupted stay cases
- § 17:81 — —Co-located discharges and readmittances
- § 17:82 — —Additional issues for co-located facilities
- § 17:83 —Payment system adjustments—Admission threshold for non-co-located patient admissions
- § 17:84 — —Site neutral payments
- § 17:85 — —New market basket and other adjustments
- § 17:86 —Calculation of the proposed standard federal payment rate
- § 17:87 —Temporary moratorium on new facilities and beds
- § 17:88 Generally—Payment provisions—Quality data
- § 17:89 — —Medicare productivity adjustment
- § 17:90 — —Medicare market basket adjustments

XI. AMBULATORY SURGICAL CENTER SERVICES

- § 17:91 Generally

XII. MEDICARE OUTPATIENT PRESCRIPTION DRUG COVERAGE

- § 17:92 Medicare payment for Part B drugs

TABLE OF CONTENTS

§ 17:93 Medicare payment for Part D drugs

Appendix 17:1. 2021 Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; New Categories for Hospital Outpatient Department Prior Authorization Process; Clinical Laboratory Fee Schedule; Laboratory Date of Service Policy; Overall Hospital Quality Star Rating Methodology; Physician-Owned Hospitals; Notice of Closure of Two Teaching Hospitals and Opportunity To Apply for Available Slots, Radiation Oncology Model; and Reporting Requirements for Hospitals and Critical Access Hospitals (CAHs) To Report COVID-19 Therapeutic Inventory and Usage and To Report Acute Respiratory Illness During the Public Health Emergency (PHE) for Coronavirus Disease 2019 (COVID-19)

CHAPTER 18. THE MEDICAID PROGRAM

I. OVERVIEW

§ 18:1 Generally

II. STATE MEDICAID PROGRAM ADMINISTRATION

§ 18:2 Generally

III. ELIGIBILITY

§ 18:3 Generally

IV. COVERAGE OF SERVICES

§ 18:4 Generally

V. REIMBURSEMENT

§ 18:5 Generally

§ 18:6 General payment standards

§ 18:7 Service-specific payment standards—Institutional services

§ 18:8 —Noninstitutional services

§ 18:9 — —Hospices

§ 18:10 — —Drugs

- § 18:11 — —Outpatient hospital and clinic services and physician billing for clinical lab services
- § 18:12 — —Physicians
- § 18:13 — —Payments to managed care plans

VI. SPECIAL LIMITATIONS: PRESCRIPTION DRUGS

- § 18:14 Generally
- § 18:15 Rebate amounts
- § 18:16 —Brand-name drugs, authorized generics
- § 18:17 —Generic drugs
- § 18:18 Mechanics of rebate payments
- § 18:19 Expanded drug coverage
- § 18:20 Rebates for Medicaid managed care organization (MCO) utilization
- § 18:21 Effect upon pharmacy reimbursement
- § 18:22 Pharmaceutical manufacturer and importer “industry fees”

VII. PROVIDER CONTRIBUTIONS AND TAXES

- § 18:23 Introduction
- § 18:24 Terms of Medicaid voluntary contribution and provider-specific tax amendments of 1991
- § 18:25 —Provider-related contributions and donations
- § 18:26 —Provider-specific taxes
- § 18:27 States with provider donation, contribution, or tax programs
- § 18:28 —Hospital donation programs
- § 18:29 —Taxes on provider costs or revenues
- § 18:30 —Provider licenses and fees

VIII. REGULATED ADMISSIONS AND RATE EQUALIZATION

- § 18:31 Generally
- § 18:32 Medicare participation requirements
- § 18:33 Antidiscrimination statutes
- § 18:34 Minimum occupancy requirements

CHAPTER 19. OTHER TYPES OF THIRD-PARTY PAYORS

- § 19:1 Introduction
- § 19:2 Private insurers
- § 19:3 Department of Veterans Affairs (VA) programs
- § 19:4 TRICARE (formerly known as the Civilian Health and

TABLE OF CONTENTS

- Medical Program of the Uniformed Services
(CHAMPUS)
- § 19:5 Federal Employee Health Benefits Program (FEHBP)
- § 19:6 Public Health Services (PHS) programs

**CHAPTER 20. OTHER FEDERAL LAWS
AFFECTING HEALTH CARE
TRANSACTIONS**

**I. ANTIDISCRIMINATION LAWS: THE AMERICANS
WITH DISABILITIES ACT OF 1990; SECTION 504
OF THE REHABILITATION ACT OF 1973; TITLE
VI OF THE CIVIL RIGHTS ACT OF 1964;
SECTION 1557 OF THE AFFORDABLE CARE ACT
AND OTHER FEDERAL LAWS**

- § 20:1 The Americans With Disabilities Act of 1990—
Introduction
- § 20:2 —Overview of Title III
- § 20:3 — —Definitions of Public Accommodations and
Commercial Facilities
- § 20:4 — —Health Care Providers: Public Accommodations
or Commercial Facilities?
- § 20:5 — —Obligations under Title III for places of public
accommodation
- § 20:6 — —Tax benefits for compliance with ADA
- § 20:7 — —Obligations of health care providers as tenants
or building owners
- § 20:8 — —Commercial facilities
- § 20:9 —Conclusion
- § 20:10 Section 504 of the Rehabilitation Act of 1973
- § 20:11 —Overview—Coverage: “any program or activity
receiving federal financial assistance”
- § 20:12 — —Requirements
- § 20:13 —OCR review of compliance with § 504, Title VI of
the Civil Rights Act of 1964, and other federal
antidiscrimination laws
- § 20:14 —Requirements for compliance
- § 20:15 —Conclusion
- § 20:16 Section 1557 of the Affordable Care Act:
Nondiscrimination Requirements

II. ANTITRUST CONSIDERATIONS

- § 20:17 Generally
- § 20:18 Mergers, acquisitions, and other horizontal
arrangements

HEALTH FINANCIAL TRANSACTIONS

- § 20:19 Joint ventures and other collaborative arrangements
- § 20:20 Guidance on antitrust enforcement: statements of antitrust enforcement policy in the health care area
- § 20:21 —Summary of the 1994 statements
- § 20:22 — —Mergers among hospitals
- § 20:23 — —Hospital joint ventures involving high-technology or other expensive health care equipment
- § 20:24 — —Hospital joint ventures involving specialized clinical or other expensive health care services
- § 20:25 — —Providers' collective provision of information to purchasers of health care services
- § 20:26 — — —Providers' collective provision of non-fee-related information to purchasers of health care services
- § 20:27 — — —Providers' collective provision of fee related information to purchasers of health care services
- § 20:28 — —Provider participation in exchanges of price and cost information
- § 20:29 — —Joint purchasing arrangements among health care providers
- § 20:30 — —Physician network joint ventures
- § 20:31 — —Analytical principles relating to multiprovider networks
- § 20:32 — —Department of Justice expedited business review procedure and Federal Trade Commission advisory opinion procedure
- § 20:33 —Evaluation of the 1994 statements
- § 20:34 —Summary of the 1996 statements
- § 20:35 — —Physician network joint ventures
- § 20:36 — —Multiprovider networks
- § 20:37 — —Evaluation of the 1996 statements
- § 20:38 Guidance on antitrust enforcement: 2011 Statement on accountable care organizations
- § 20:39 Enforcement developments
- § 20:40 —Mergers
- § 20:41 —Anti-steering provisions, exclusive dealing provisions and “most-favored nations” clauses
- § 20:42 Price fixing of labor
- § 20:43 The effects of COVID-19 on antitrust enforcement

III. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS ACT OF 1988

- § 20:44 Introduction
- § 20:45 Laboratories subject to CLIA 1988
- § 20:46 Requirements for certification
- § 20:47 Types of certificates
- § 20:48 Certificates of waiver

TABLE OF CONTENTS

- § 20:49 Complexity considerations
- § 20:50 Personnel qualifications
- § 20:51 —Laboratory director
- § 20:52 —Clinical consultant
- § 20:53 —Technical consultant
- § 20:54 —Testing personnel
- § 20:55 Quality system
- § 20:56 Proficiency testing
- § 20:57 Inspections and accreditation
- § 20:58 Enforcement

IV. FEDERAL PATIENT ANTI-DUMPING STATUTE

- § 20:59 Summary of the Anti-Dumping Statute
- § 20:60 When a patient “comes to the emergency department”
- § 20:61 Conducting a medical screening examination
- § 20:62 Providing stabilizing treatment or appropriate transfer
- § 20:63 Obtaining prior authorization for emergency care
- § 20:64 Application of EMTALA to hospital inpatients
- § 20:65 Administrative requirements under EMTALA
- § 20:66 Physician on-call coverage
- § 20:67 Obligations of receiving hospitals
- § 20:68 Obligations of physicians
- § 20:69 Penalties for EMTALA violations

V. CONTROLLED SUBSTANCES ACT OF 1970

- § 20:70 Overview and administration
- § 20:71 Registration of each principal place of business
- § 20:72 —Warehouses
- § 20:73 —Registrant’s sales office
- § 20:74 —Practitioner’s second office
- § 20:75 —Freight forwarding facility
- § 20:76 Separate registration for independent activities
- § 20:77 Registration of persons dispensing controlled substances
- § 20:78 Registration criteria and procedures
- § 20:79 Implications of a change of ownership of a registered entity
- § 20:80 Penalties for failure to register and other registration violations
- § 20:81 Recent DEA settlements
- § 20:82 Conclusion

VI. FEDERAL FOOD, DRUG AND COSMETIC ACT (FFDCA)

- § 20:83 Generally

- § 20:84 Premarket approval process
- § 20:85 Postmarket surveillance and enforcement activities
- § 20:86 Effect of FDA approval on coverage under the Medicaid and Medicare programs

VII. THE DATA BANKS

- § 20:87 Generally
- § 20:88 When and where to report
- § 20:89 Information that must be reported—Malpractice payments
- § 20:90 —Adverse actions
- § 20:91 —Exclusions from Medicare and Medicaid programs
- § 20:92 Sanctions for failure to report
- § 20:93 Duty of hospitals to obtain information
- § 20:94 Confidentiality of reported information
- § 20:95 Practical considerations

VIII. HILL-BURTON ACT AND STATE CHARITY CARE REQUIREMENTS

- § 20:96 History and overview
- § 20:97 Sale of Facilities with Hill-Burton Obligations to For-Profit Entities
- § 20:98 Uncompensated care assurance—Applicability
- § 20:99 —Calculation of the annual compliance level
- § 20:100 —Prepare and publish an allocation plan and display notice of free care
- § 20:101 —Determine eligibility for uncompensated services
- § 20:102 —Liability for uncompensated care services
- § 20:103 Community services assurances—Overview
- § 20:104 —Nondiscriminatory admission of community residents
- § 20:105 —Emergency services
- § 20:106 —Participation in third-party programs
- § 20:107 —Duration of community service obligation
- § 20:108 State law requirements
- § 20:109 Federal Health Resources and Services Administration issues answers to frequently asked questions relating to the Hill-Burton Act

IX. PRESCRIPTION DRUG MARKETING ACT OF 1987 (PDMA)

- § 20:110 Generally

TABLE OF CONTENTS

**X. MEDICAL DEVICE FACILITY USER
REPORTING REQUIREMENTS UNDER SAFE
MEDICAL DEVICES ACT OF 1990 (SMDA)**

- § 20:111 Health Resources and Services Administration Hill-Burton Act FAQs
- § 20:112 Introduction
- § 20:113 Device user facility reporting
- § 20:114 —Key terms: device user facility, device, and serious injury—Device user facility
- § 20:115 — —Device
- § 20:116 — —Serious injury
- § 20:117 —User facility reporting requirements
- § 20:118 — —Reporting deaths
- § 20:119 — —Reporting serious injuries
- § 20:120 — —Recordkeeping requirements
- § 20:121 — —Decisionmaking on submitting reports
- § 20:122 —Annual reports
- § 20:123 —Record retention
- § 20:124 —Limits on disclosure and admissibility
- § 20:125 —Enforcement

**XI. STATUTES APPLICABLE TO HEALTH CARE
GOVERNMENT CONTRACTORS**

- § 20:126 Generally
- § 20:127 Labor requirements
- § 20:128 Subcontracting and assignment

XII. FAIR LABOR STANDARDS ACT

- § 20:129 Fair Labor Standards Act in healthcare settings
- Appendix 20:1. Department of Health and Human Services, Office of Civil Rights, Assurance of Compliance (HHS Form-690)
- Appendix 20:2. Clinical Laboratory Application to U.S. Department of Health and Human Services
- Appendix 20:3. Laboratory Personnel Report to U.S. Department of Health and Human Services
- Appendix 20:4. Model Trust Agreement Pursuant to Section 609 of the Public Health Service Act
- Appendix 20:5. DOJ and FTC Protocol for Coordination in Merger Investigations
- Appendix 20:6. Joint Statement of the Antitrust Division

HEALTH FINANCIAL TRANSACTIONS

- and FTC on CON Laws and Alaska Senate
Bill 62
- Appendix 20:7. Crouse Health Hospital Advisory Opinion re
Robinson-Patman Act
- Appendix 20:8. FTC Guidance from Staff of the Bureau of
Competition's Health Care Division on
Requesting and Obtaining an Advisory
Opinion
- Appendix 20:9. Frequently Asked Questions About Filing
Agreements with the FTC Pursuant to the
Medicare Prescription Drug, Improvement,
and Modernization Act of 2003
- Appendix 20:10. FTC Working Paper: Simulating Hospital
Merger Simulations

Table of Contents

PART III. QUICK REFERENCE GUIDE TO THE HEALTH CARE INDUSTRY: PLAYERS AND PAYORS (CONTINUED)

CHAPTER 20. OTHER FEDERAL LAWS AFFECTING HEALTH CARE TRANSACTIONS (CONTINUED)

- Appendix 20:11. Overview of FTC Actions in Health Care Services and Products, August 2018
- Appendix 20:12. Letter in response to the Honorable Dan K. Morhaim, M.D., Maryland House of Delegates, regarding Maryland House Bill 857 and the use by hospitals, insurers, and others of certification programs for physicians in medical specialties and, in particular, the Maintenance of Certification (“MOC”) program as currently implemented by the American Board of Medical Specialties (“ABMS”) and its member boards
- Appendix 20:13. FTC Working Paper 339—Prices for Medical Services Vary Within Hospitals, but Vary More Across Them, December 2018
- Appendix 20:14. FTC Working Paper 334 (Revised)—Simulating Hospital Merger Simulations, September 2018
- Appendix 20:15. FTC Working Paper 337—The effects of physician and hospital integration on Medicare beneficiaries’ health outcomes, July 2018
- Appendix 20:16. FTC Guidance on Marketing of Refractive Eye Care Surgery: Guidance for Eye Care Providers
- Appendix 20:17. Antitrust Guidance for Human Resource Professionals, Department of Justice, Antitrust Division/Federal Trade Commission, October 2016

HEALTH FINANCIAL TRANSACTIONS

- Appendix 20:18. HRSA Provider’s Guide to the Hill-Burton Uncompensated Services Regulations
- Appendix 20:19. Overview of FTC Actions in Health Care Services and Products, April 2020
- Appendix 20:20. EMTALA State Operations Manual Appendix V—Interpretive Guidelines—Responsibilities of Medicare Participating Hospitals in Emergency Cases (Revised 7-19-19)
- Appendix 20:21. Request for Additional Information and Documentary Material Issued to [Weebyewe Corporation](February 2021)
- Appendix 20:22. Model Order to File Special Report Regarding Physician Group and Healthcare Facility Mergers (January 2021)
- Appendix 20:23. FTC’s The Most Frequently Asked HSR Questions
- Appendix 20:24. OIG Practical Guidance for Health Care Governing Boards on Compliance Oversight
- Appendix 20:25. State Operations Manual Appendix V - Interpretive Guidelines - Responsibilities of Medicare Participating Hospitals in Emergency Cases - Rev. 7-19-19
- Appendix 20:26. Washington AG Guidance on Healthcare Transactions Notification Requirement
- Appendix 20:27. Guidance For Industry — Prescription Drug Marketing Act (PDMA) Requirements — Questions and Answers
- Appendix 20:28. FTC Press Release regarding HSR Early Termination After a Second Request Issues (March 12, 2021)
- Appendix 20:29. Federal Trade Commission and Justice Department Seek to Strengthen Enforcement Against Illegal Mergers (Press release — January 18, 2022)
- Appendix 20:30. FTC Staff Advisory Opinion Letter from Markus Meier to Doylestown Health Foundation (September 2, 2021)
- Appendix 20:31. CMS Frequently Asked Questions for Hospitals and Critical Access Hospitals regarding EMTALA (April 30, 2020)
- Appendix 20:32. FTC Frequently Asked Questions About Merger Consent Order Provisions

TABLE OF CONTENTS

- Appendix 20:33. FDA drug supply chain security act product tracing requirements frequently asked questions (updated September 20, 2022)
- Appendix 20:34. FDA Guidance Document—Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry
- Appendix 20:35. Federal Trade Commission Staff Submission to New York State Health Department Regarding the Certificate of Public Advantage Application of State University of New York Upstate Medical University and Crouse Health System, Inc. (October 7, 2022)
- Appendix 20:36. FDA Guidance for Industry Prescription Drug Marketing Act—Donation of Prescription Drug Samples to Free Clinics
- Appendix 20:37. 7-3.300—Antitrust Division Leniency Policy and Procedures
- Appendix 20:38. Frequently Asked Questions About the Antitrust Division’s Leniency Program
- Appendix 20:39. DOJ and FTC 44th Hart-Scott-Rodino Annual Report (FY2021) (February 2023)
- Appendix 20:40. FTC Letter addressing North Carolina Senate Bill 743, Purporting to Give State Action Defense to UNC Health’s Collaborative Activities
- Appendix 20:41. FTC petition in *FTC v. Louisiana Children’s Medical Center, 1:23-cv-01103 (D.C. Dist.)*
- Appendix 20:42. HHS Guidance on Effective Communication for Persons who are Deaf or Hard of Hearing
- Appendix 20:43. DOJ and FTC Merger Guidelines (December 18, 2023)
- Appendix 20:44. FTC Novant Health/Community Health Administrative Complaint to block merger (January 25, 2024)
- Appendix 20:45. HHS Statement Including new EMTALA Complaint form: Biden-Harris Administration Reaffirms Commitment to EMTALA Enforcement (July 2, 2024)
- Appendix 20:46. Overview of FTC actions in health care services and products—January 2025

- Appendix 20:47. FTC analysis of agreement containing consent order to aid public comment—In the Matter of Welsh Carson, Anderson, and Stowe, File No. 201 0031
- Appendix 20:48. FTC Checklist for Submitting an HSR Filing
- Appendix 20:49. Antitrust Complaint in U.S., et al. v Unitedhealth Group Incorporated, et al., 1:24-cv-03267-JKB, (D. MD)
- Appendix 20:50. FTC Staff Submission to Indiana Health Department Regarding the COPA Application of Union Health and Terre Haute Regional Hospital
- Appendix 20:54. Federal Trade Commission Supplemental Staff Submission to Indiana Health Department Regarding 2025 Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital
- Appendix 20:55. FTC Topic and Yearly Indices of Health Care Antitrust Advisory Opinions by Commission and Staff (June 2025)

PART IV. LEGISLATION, REGULATIONS, AND STUDIES

CHAPTER 21. HEALTH CARE LEGISLATION

I. IN GENERAL

§ 21:1 Introduction

II. HEALTH POLICY PROVISIONS OF SELECT FEDERAL LEGISLATION

§ 21:2 Balanced Budget Act

§ 21:3 BBA “Givebacks”: BBRA and BIPA

§ 21:4 Other major Medicare payment legislation

§ 21:5 COVID-19 Public Health Emergency Transition

§ 21:6 Preventing surprise medical bills

III. HEALTH REFORM UNDER THE OBAMA ADMINISTRATION AND BEYOND

§ 21:7 Generally

§ 21:8 Health provisions of the American Recovery and Reinvestment Act

TABLE OF CONTENTS

- § 21:9 The Affordable Care Act
- § 21:10 —Health insurance reforms
- § 21:11 —The role of public programs
- § 21:12 —Improving the quality and efficiency of health care
- § 21:13 —Prevention of chronic disease and improving public health
- § 21:14 —Health care workforce
- § 21:15 —Transparency and program integrity
- § 21:16 —Improving access to innovative medical therapies
- § 21:17 —Community Living Assistance Services and Supports (CLASS) program
- § 21:18 —Revenue provisions/health industry fees and taxes
- § 21:19 —Health industry impact and outlook
- § 21:20 Middle Class Tax Relief and Job Creation Act
- § 21:21 Budget Control Act (Sequestration) and the American Taxpayer Relief Act
- § 21:22 Bipartisan Budget Act of 2013
- § 21:23 Protecting Access to Medicare Act of 2014
- § 21:24 Medicare Access and CHIP Reauthorization Act of 2015
- § 21:25 Consolidated Appropriations Act of 2015
- § 21:26 21st Century Cures Act
- § 21:27 Tax Cuts and Jobs Act (TCJA)

IV. STATE HEALTH CARE REFORM INITIATIVES

- § 21:28 Hospital Price Transparency
- § 21:29 Generally
- § 21:30 Medicaid reform
- § 21:31 Managed care reform
- § 21:32 Parity in Mental Health and Substance Abuse Benefits
- § 21:33 Children’s health reform initiatives
- § 21:34 Statewide reforms
- § 21:35 —Maryland
- § 21:36 —Oregon
- § 21:37 —Massachusetts

CHAPTER 22. EXECUTIVE BRANCH AND OTHER HEALTH POLICY PLAYERS

I. EXECUTIVE BRANCH AND OTHER HEALTH POLICY PLAYERS

- § 22:1 Background on the regulatory process

II. STUDIES AFFECTING HEALTH CARE REGULATION AND REFORM

- § 22:2 Generally

**III. COST EFFECTIVENESS AND OUTCOMES
RESEARCH**

§ 22:3 Agency for Healthcare Research and Quality (AHRQ)

§ 22:4 Legislative developments: ARRA and the ACA

Table of Laws and Rules

Table of Cases

Index